Cost-effectiveness of bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitor in the treatment of non-ST-segment elevation acute coronary syndromes

Matthias Schwenkglenks, John E Brazier, Thomas D Szucs, Keith A A Fox

Research output: Contribution to journalArticlepeer-review

Abstract

This study sought to assess the cost-effectiveness of bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitor (GPI) in thienopyridine-treated non-ST-segment elevation acute coronary syndrome (NSTE-ACS) patients undergoing early or urgent invasive management, from a United Kingdom National Health Service perspective.
Original languageEnglish
Pages (from-to)24-33
Number of pages10
JournalValue in Health
Volume14
Issue number1
DOIs
Publication statusPublished - 2011

Fingerprint

Dive into the research topics of 'Cost-effectiveness of bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitor in the treatment of non-ST-segment elevation acute coronary syndromes'. Together they form a unique fingerprint.

Cite this